164 related articles for article (PubMed ID: 38254190)
1. Immune characteristics of dedifferentiated retroperitoneal liposarcomas and the reliability of regional samples in evaluating their tumor immune microenvironments.
Zhou C; Li M; Ren Y; Miao F; Wang Y; Wu T; Gou X; Li W
World J Surg Oncol; 2024 Jan; 22(1):25. PubMed ID: 38254190
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma.
Yan L; Wang Z; Cui C; Guan X; Dong B; Zhao M; Wu J; Tian X; Hao C
Cancer Sci; 2019 Oct; 110(10):3038-3048. PubMed ID: 31385405
[TBL] [Abstract][Full Text] [Related]
3. Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma.
Shen YC; Hsu CL; Jeng YM; Ho MC; Ho CM; Yeh CP; Yeh CY; Hsu MC; Hu RH; Cheng AL
J Hepatol; 2020 Mar; 72(3):489-497. PubMed ID: 31634533
[TBL] [Abstract][Full Text] [Related]
4. Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas.
Oike N; Kawashima H; Ogose A; Hatano H; Ariizumi T; Yamagishi T; Murayama Y; Umezu H; Imai C; Hayashi M; Endo N
Cancer Immunol Immunother; 2021 Dec; 70(12):3489-3499. PubMed ID: 33893830
[TBL] [Abstract][Full Text] [Related]
5. Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis.
de Vreeze RS; de Jong D; Tielen IH; Ruijter HJ; Nederlof PM; Haas RL; van Coevorden F
Mod Pathol; 2009 Feb; 22(2):223-31. PubMed ID: 18820664
[TBL] [Abstract][Full Text] [Related]
6. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma.
Horvai AE; DeVries S; Roy R; O'Donnell RJ; Waldman F
Mod Pathol; 2009 Nov; 22(11):1477-88. PubMed ID: 19734852
[TBL] [Abstract][Full Text] [Related]
7. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma.
Choi B; Lee JS; Kim SJ; Hong D; Park JB; Lee KY
Cancer Lett; 2020 May; 478():56-69. PubMed ID: 32145342
[TBL] [Abstract][Full Text] [Related]
9. Characterising the immune microenvironment in liposarcoma, its impact on prognosis and the impact of radiotherapy.
Snow H; Mitchell C; Hendry S; McKinley M; Byrne D; Ngan S; Chander S; Chu J; Desai J; Bae S; Henderson M; Choong P; Gyorki D
J Surg Oncol; 2021 Jan; 123(1):117-126. PubMed ID: 33084061
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity.
Coindre JM; Hostein I; Maire G; Derré J; Guillou L; Leroux A; Ghnassia JP; Collin F; Pedeutour F; Aurias A
J Pathol; 2004 Jul; 203(3):822-30. PubMed ID: 15221942
[TBL] [Abstract][Full Text] [Related]
11. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma.
Coindre JM; Mariani O; Chibon F; Mairal A; De Saint Aubain Somerhausen N; Favre-Guillevin E; Bui NB; Stoeckle E; Hostein I; Aurias A
Mod Pathol; 2003 Mar; 16(3):256-62. PubMed ID: 12640106
[TBL] [Abstract][Full Text] [Related]
12. Perioperative strategy and outcome in giant retroperitoneal dedifferentiated liposarcoma-results of a retrospective cohort study.
Bachmann R; Eckert F; Gelfert D; Strohäker J; Beltzer C; Ladurner R
World J Surg Oncol; 2020 Nov; 18(1):296. PubMed ID: 33183309
[TBL] [Abstract][Full Text] [Related]
13. Retroperitoneal dedifferentiated liposarcoma with osteosarcomatous components: a case report.
Fujii T; Arai T; Sakon M; Sawano S; Momose Y; Ishii K; Miwa S
Int J Clin Exp Pathol; 2013; 6(7):1427-31. PubMed ID: 23826426
[TBL] [Abstract][Full Text] [Related]
14. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
15. A long-term survivor of advanced retroperitoneal dedifferentiated liposarcoma: a successful multimodal approach with extended resection and chemotherapy.
Nakahashi K; Yokoyama Y; Fukaya M; Igami T; Mizuno T; Yamaguchi J; Onoe S; Watanabe N; Ebata T
Nagoya J Med Sci; 2022 Feb; 84(1):200-207. PubMed ID: 35392006
[TBL] [Abstract][Full Text] [Related]
16. Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma.
Cui L; Yan L; Guan X; Dong B; Zhao M; Lv A; Liu D; Wang Z; Liu F; Wu J; Tian X; Hao C
Front Oncol; 2021; 11():739139. PubMed ID: 34868934
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma.
Tseng WW; Malu S; Zhang M; Chen J; Sim GC; Wei W; Ingram D; Somaiah N; Lev DC; Pollock RE; Lizée G; Radvanyi L; Hwu P
Sarcoma; 2015; 2015():547460. PubMed ID: 25705114
[TBL] [Abstract][Full Text] [Related]
18. Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.
Zhang L; Chen Y; Wang H; Xu Z; Wang Y; Li S; Liu J; Chen Y; Luo H; Wu L; Yang Y; Zhang H; Peng H
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34140315
[TBL] [Abstract][Full Text] [Related]
19. [An exceptional association between retroperitoneal dedifferentiated liposarcoma and well differentiated pericolonic liposarcoma: about a case].
Sinaa M
Pan Afr Med J; 2016; 25():254. PubMed ID: 28293370
[TBL] [Abstract][Full Text] [Related]
20. Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD-L1, IDO, TIM-3, FOXP3+ and CD8 expressions in patients with advanced esophageal squamous cell carcinoma.
Zhang S; Cai H; Huang J; Wang G
Thorac Cancer; 2022 Dec; 13(23):3284-3294. PubMed ID: 36288460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
